INHIBITOR Therapeutics, Inc. is a publicly traded pharmaceutical company (OTCQB:INTI) focused on developing and commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders. SUBA-Itraconazole, the company’s lead product candidate, is a patented, oral formulation of the currently FDA approved and marketed, well-understood, anti-fungal drug, itraconazole, which, when studied to treat patients with cancer, has demonstrated activity against multiple tumor types. INHIBITOR is developing SUBA-Itraconazole for late-stage, metastatic castrate-resistant prostate cancer (mCRPC) and late-stage non-squamous non-small cell lung cancer (NSCLC). INHIBITOR is the exclusive U.S. licensee for SUBA-Itraconazole for the treatment of certain cancers and non-cancerous proliferation disorders. INHIBITOR’s lead programs are clinically de-risked due to itraconazole’s prior FDA approval (505(b)(2) pathway), with proven bioavailability, safety and anti-tumor efficacy previously demonstrated in an INHIBITOR clinical trial testing SUBA-Itraconazole in 38 patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS). Solid clinical execution was demonstrated with the completion of a Phase 2b trial in BCCNS, confirming a low toxicity safety profile when compared to published data for other oncology drugs that inhibit the same pathway as a treatment for basal cell carcinoma (BCC) lesions.
View Top Employees from INHIBITOR Therapeutics, Inc.Website | https://inhibitortx.com/ |
Revenue | $24 million |
Employees | 4 (0 on RocketReach) |
Founded | 2013 |
Address | 4830 W. Kennedy Blvd. Suite 600, Tampa, Florida 33609, US |
Phone | (813) 830-7489 |
Fax | (813) 509-2417 |
Technologies |
JavaScript,
HTML,
PHP
+22 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Biotechnology, Pharmaceuticals, Healthcare |
SIC | SIC Code 80 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular INHIBITOR Therapeutics, Inc. employee's phone or email?
The INHIBITOR Therapeutics, Inc. annual revenue was $24 million in 2024.
INHIBITOR Therapeutics, Inc. is based in Tampa, Florida.
The NAICS codes for INHIBITOR Therapeutics, Inc. are [325, 32, 3254].
The SIC codes for INHIBITOR Therapeutics, Inc. are [80, 283, 28].